DXC Technology’s fourth quarter results were met with a negative market response, reflecting investor concerns despite stable headline revenue and a significant non-GAAP earnings per share surprise.

Welcome back. I’m Matt Bird your host. We are coming off another panel and I’ve got with me next the chief medical officer for DXC Technologies of North America, George Mathew. George, how are you ...